Loading patent…
AssigneeAjinomoto Co., Inc.
InventorsChisato Makino, Nobutaka Ninomiya, Haruo Orita, Hidetoshi Sakai, Akira Yabuki, Nobuo Kato, Shigeru Shioya
Estimating the term…
There is provided a single preparation which directly decreases both of the post prandial blood glucose level and the fasting blood glucose level close to normal levels, by release-sustaining a drug capable of decreasing the post prandial blood glucose level of diabetic patients close to the normal level, or mixing a controlled release drug capable of decreasing the post prandial blood glucose level close to the normal level with an immediate release drug. It is particularly preferable that the drug capable of decreasing the post prandial blood glucose level close to the normal level is nateglinide, repaglinide, or mitiglinide (KAD-1229).
A controlled release oral anti-diabetic preparation comprising at least one fast-acting post prandial blood glucose regulator.
An anti-diabetic preparation for oral administration comprising an fast-acting post prandial blood glucose regulator having a coating comprising hydroxypropylmethyl cellulose phthalate sufficient to provide continuous release of said drug as the sole active ingredient for decreasing blood glucose levels.
A method of controlling both post prandial blood glucose levels and fasting blood glucose levels by orally administering to a patient an effective amount of a controlled release composition comprising at least one fast-acting post prandial blood glucose regulator.
Dependencies are inferred from the claim text.